Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the Methylation Status in Gliomas and Other Tumors

The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene is an important predictive biomarker for benefit from alkylating agent therapy in glioblastoma. Our model MGMT-STP27 allows prediction of the methylation status of the MGMT promoter by using data from the HumanMethylationBeadChip (Illumina, HM-27K, and HM-450K) that is publically available for many cancer data sets. Here, we present investigations addressing the impact of the context of genetic and epigenetic alterations and tumor type on the classification and report on technical aspects, such as robustness of cutoff definition and preprocessing of the data.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Source Type: research